Back to News
Market Impact: 0.25
Quoin Pharma Surges 45% In Pre-Market On Positive QRX003 Data And $50M Private Placement
Source: Nasdaq
Company FundamentalsPrivate Markets & Venture
Quoin Pharmaceuticals reported positive interim results from its Phase 2/3 study of QRX003 in Netherton Syndrome. The company also announced a private placement financing (details truncated in the article), which may support ongoing clinical and operating needs. Overall, the clinical update is a near-term positive catalyst, though financing could temper sentiment.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
QNRX0.35
More News
- ‘If nothing is done, it’s almost inevitable’: Ukraine’s Yuriy Ryzhenkov on why steelmaking is on the brink of collapse as Russian bombing intensifies
- Why is LG Innotek stock plunging today?
- TotalEnergies, KKR expand U.S. solar venture with 700 MW addition
- TSMC expected to report sixth straight quarter of record profit thanks to AI boom
- Vår Energi cuts 2026 output forecast; Q3 production at 369,000 boepd
- CXMT: How big is its market threat to Samsung, SK Hynix and Micron?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Build an Automated Research Process for a Fund
- Weekly Update: AI-Powered Report Editing, Investor Relations, and Enhanced Search